Teva Pharm Stock Price, News & Analysis

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) will host an Investor Day on May 18, 2023, at the New York Stock Exchange in New York City. The event, starting at 12:00 p.m. Eastern Time, will outline Teva's new growth strategy and portfolio priorities. President and CEO Richard Francis will present a strategic framework focused on growth and innovation, highlighting key assets and the company’s R&D pipeline. The presentations will emphasize Teva's goals related to growth and profitability. Attendance is by invitation only, with a live webcast available on Teva’s Investor Relations website, ensuring broader access to financial analysts and institutional investors.

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced it will release its first quarter 2023 financial results on May 10, 2023 at 7:00 a.m. ET. Following this, a conference call and live webcast will take place at 8:00 a.m. ET. Interested participants must register in advance for the call, accessible via Teva's website. Teva emphasizes its commitment to developing medications that enhance lives, offering a diverse portfolio of over 3,500 products. The company has a significant global presence in both generic and innovative medicines, serving approximately 200 million people daily, supported by a complex supply chain. The press release includes a cautionary note about forward-looking statements, highlighting that actual results may differ due to various risks.

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) has received a complete response letter (CRL) from the U.S. FDA regarding its partner Alvotech's (NASDAQ: ALVO) Biologics License Application for AVT02, a biosimilar to Humira (adalimumab). The FDA's CRL indicates that the application cannot be approved due to deficiencies identified at Alvotech's manufacturing facility, which need resolution. Despite this setback, Teva reaffirms its commitment to leadership in the biosimilars market and expresses optimism about its product pipeline, including further advancements with AVT02.

Teva Pharmaceuticals announced the FDA approval of AUSTEDO XR (deutetrabenazine) once-daily extended-release tablets on February 17, 2023. AUSTEDO XR is therapeutically equivalent to the existing twice-daily AUSTEDO tablets for adults with tardive dyskinesia (TD) and chorea associated with Huntington’s disease (HD). This new formulation is expected to be available commercially later this year. Teva will present data supporting AUSTEDO XR's approval at the American Academy of Neurology (AAN) Annual Meeting on April 22-27, 2023, demonstrating bioequivalence and safety across various dose strengths (6 mg, 12 mg, and 24 mg). Teva's research highlights the improved therapeutic options for patients living with TD and HD chorea.

Teva Pharmaceutical Industries (NYSE: TEVA) has partnered with Rimidi to implement a respiratory patient monitoring program at Desert Oasis Healthcare in California. Utilizing data from Teva's Digihaler System, the program aims to enhance asthma management and reduce costs and hospitalizations. Digihaler is recognized as the only smart inhaler providing objective data to aid in treatment planning. Teva and Rimidi plan to expand this initiative to other health systems, emphasizing their commitment to integrating technology in healthcare to improve patient outcomes and predictive capabilities in asthma management.

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced early tender results for its tender offers related to several series of its senior notes. The company is increasing the tender caps for its Pool 1 Notes to $1.65 billion, Pool 2 Notes to $450 million, and Pool 3 Notes to approximately $293.3 million, while the Pool 4 Notes cap remains at $250 million. The total maximum amount for the offers is $2.5 billion. Teva aims to manage and extend its debt maturity profile and plans to fund these offers through proceeds from a recent public offering and cash reserves. Settlement is expected on March 15, 2023, and the offers will expire on March 27, 2023.

Teva Pharmaceuticals, in collaboration with NATCO Pharma, has launched additional strengths of its generic lenalidomide capsules in the U.S., including 2.5 mg and 20 mg doses. This follows the introduction of four other strengths in March 2022, making all formulations of lenalidomide available in the U.S. The generic is critical for treating multiple myeloma, myelodysplastic syndromes, and mantle cell lymphoma. With nearly 500 generic products, Teva leads the market and holds around 100 pending first-to-file opportunities. Lenalidomide's annual sales reached $2.9 billion as of January 2023, enhancing Teva's position in the generics market.